Axsome Therapeutics (AXSM) director sells 17,537 shares under Rule 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. director Mark Coleman reported open-market sales of 17,537 shares of common stock over three trading days. He sold 6,000 shares on May 29 at a weighted average price of $233.46, 6,000 shares on June 1 at $230.30, and 5,537 shares on June 2 at $223.39 per share.

According to the filing, these transactions involved underlying shares from previously exercised stock options and were executed under a pre-approved Rule 10b5-1 trading plan. After these sales, Coleman holds 29,603 shares directly and 403,856 shares indirectly through an entity for which he has voting and dispositive power.

Insider Trade Summary 10b5-1

Net Seller: 17,537 shares ($4,019,470)

Net Sell 4 txns

Insider Coleman Mark

Role null

Sold 17,537 shs ($4.02M)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,537	$223.39	$1.24M
Sale	Common Stock	6,000	$230.30	$1.38M
Sale	Common Stock	6,000	$233.46	$1.40M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 29,603 shares (Direct, null); Common Stock — 403,856 shares (Indirect, See Footnote)

Footnotes (1)

Represents the sale of underlying shares of previously exercised stock options. Such transaction was pursuant to a pre-approved 10b5-1 plan. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $231.50 and $235.23. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $229.56 and $232.14. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $221.82 and $225.21. Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.

Key Figures

Total shares sold: 17,537 shares Sale price May 29: $233.46 per share Sale price June 1: $230.30 per share +3 more

6 metrics

Total shares sold 17,537 shares Open-market sales reported on Form 4

Sale price May 29 $233.46 per share Weighted average sale price on May 29, 2026

Sale price June 1 $230.30 per share Weighted average sale price on June 1, 2026

Sale price June 2 $223.39 per share Weighted average sale price on June 2, 2026

Direct holdings after sales 29,603 shares Shares directly owned following transactions

Indirect holdings 403,856 shares Shares held via entity with Coleman’s voting and dispositive power

Key Terms

Rule 10b5-1 plan, weighted average sale price, open market transactions, indirect beneficial owner, +1 more

5 terms

Rule 10b5-1 plan regulatory

"Such transaction was pursuant to a pre-approved 10b5-1 plan."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"Represents the weighted average sale price of a series of open market transactions"

open market transactions financial

"series of open market transactions with sale prices ranging"

Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.

indirect beneficial owner financial

"the reporting person is deemed to be the indirect beneficial owner of such shares."

voting and dispositive power financial

"entity, of which the reporting person has voting and dispositive power"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/02/2026 - 07:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coleman Mark

(Last)

(First)

(Middle)

C/O AXSOME THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, 29TH FLOOR

(Street)

NEW YORK

10007

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axsome Therapeutics, Inc. [ AXSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/29/2026		S⁽¹⁾⁽²⁾		6,000	D	$233.46⁽³⁾	41,140	D
Common Stock	06/01/2026		S⁽¹⁾⁽²⁾		6,000	D	$230.3⁽⁴⁾	35,140	D
Common Stock	06/02/2026		S⁽¹⁾⁽²⁾		5,537	D	$223.39⁽⁵⁾	29,603	D
Common Stock								403,856	I	See Footnote⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents the sale of underlying shares of previously exercised stock options.

2. Such transaction was pursuant to a pre-approved 10b5-1 plan.

3. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $231.50 and $235.23.

4. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $229.56 and $232.14.

5. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $221.82 and $225.21.

6. Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.

	/s/ Nick Pizzie, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Axsome Therapeutics (AXSM) director Mark Coleman report?

Mark Coleman reported selling 17,537 Axsome Therapeutics shares in open-market transactions. The sales occurred on May 29, June 1, and June 2, 2026, at weighted average prices between $223.39 and $233.46 per share, involving shares from previously exercised stock options.

At what prices did Mark Coleman sell Axsome Therapeutics (AXSM) stock?

Coleman reported weighted average sale prices of $233.46, $230.30, and $223.39 per Axsome share. Footnotes state these averages reflect multiple trades, with daily price ranges from $221.82 up to $235.23, all executed in open-market transactions.

How many Axsome Therapeutics (AXSM) shares did Mark Coleman sell in this Form 4?

The Form 4 reports Coleman sold a total of 17,537 Axsome shares. This includes 6,000 shares on May 29, 6,000 shares on June 1, and 5,537 shares on June 2, all categorized as open-market or private sale transactions.

How many Axsome Therapeutics (AXSM) shares does Mark Coleman own after these sales?

After the reported sales, Coleman directly owns 29,603 Axsome shares. The filing also shows an indirect holding of 403,856 shares through an entity over which he has voting and dispositive power, making him the indirect beneficial owner of those shares.

Were Mark Coleman’s Axsome Therapeutics (AXSM) stock sales under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were executed pursuant to a pre-approved Rule 10b5-1 trading plan. Such plans are established in advance, allowing pre-scheduled trades that are not timed in reaction to subsequent company-specific information.

Did Mark Coleman’s Axsome (AXSM) sales involve stock options?

Yes. One footnote explains the reported sales represent underlying shares from previously exercised stock options. This indicates the transactions relate to monetizing shares acquired through option exercises rather than selling newly granted or long-held common stock directly.